Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial
Circulation: Cardiovascular Interventions · 2023
DOI: 10.1161/circinterventions.122.012332 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2023. Verfasst von Kirstine Nørregaard Hansen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Odense University Hospital, Denmark (K.N.H., L.O.J., M.N., A.J., J.E.-G., K.T.V.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Biodegradable polymer drug-eluting stents were developed to improve safety and efficacy outcomes for patients undergoing percutaneous coronary intervention. However, few long-term follow-up efficacy studies are available. The study sought to investigate 5-year results from the SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome) comparing the biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES) versus the biodegradable polymer biolimus-eluting Nobori stent (N-BES).
Methods
This registry-based, randomized, multicenter, single-blinded, noninferiority trial compared O-SES and N-BES in an all-comer population. The composite primary end point, target lesion failure, consisted of cardiac death, myocardial infarction related to the target lesion, or target lesion revascularization within 1 year. Follow-up was extended to 5 years.
Results
Five-year follow-up was completed for 2521 patients (99.8%). Five-year target lesion failure did not differ between O-SES (12.4%) and N-BES (13.1%; rate ratio [RR], 0.94 [95% CI, 0.75–1.18]). Cardiac death (RR, 0.95 [95% CI, 0.67–1.34]), target myocardial infarction (RR, 1.14 [95% CI, 0.76–1.71]), target lesion revascularization (RR, 0.90 [95% CI, 0.67–1.21]), and definite stent thrombosis rates (RR, 0.73 [95% CI, 0.41–1.33]) did not differ significantly between the 2 stents. Within the first year, definite ST was significantly lower for O-SES (0.4%) compared to N-BES (1.2%; RR, 0.33 [95% CI, 0.12–0.92]), but no difference was from 1 through 5 years: O-SES 1.2% and N-BES 0.9% (RR, 1.28 [95% CI, 0.58–2.82]).
Conclusions
Five years after treatment with biodegradable polymer stents, target lesion failure did not differ among O-SES and N-BES. Definite stent thrombosis was less often seen within the first year in the O-SES but the difference was not maintained after 5 years. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT01879358.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Odense University Hospital, Denmark (K.N.H., L.O.J., M.N., A.J., J.E.-G., K.T.V.).
- Department of Cardiology, Aarhus University Hospital, Denmark (M.M., L.J., C.J.T., E.H.C.).
- Department of Cardiology, Aalborg University Hospital, Denmark (M.K.C., P.F., B.R.).
- Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (J.K.).
ORCID-Profile: Kirstine Nørregaard Hansen, Lisette Okkels Jensen, Michael Maeng, Martin Kirk Christensen, Manijeh Noori, Lars Jakobsen
Zitieren
APA
Hansen, K. N., Jensen, L. O., Maeng, M., Christensen, M. K., Noori, M., Kahlert, J., Jakobsen, L., Junker, A., Freeman, P., Ellert-Gregersen, J., Raungaard, B., Terkelsen, C. J., Veien, K. T., & Christiansen, E. H. (2023). Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.122.012332
Vancouver
Hansen KN, Jensen LO, Maeng M, Christensen MK, Noori M, Kahlert J, et al. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial. Circulation: Cardiovascular Interventions. 2023. doi:10.1161/circinterventions.122.012332
BibTeX
@article{Hansen2023,
author = {Hansen, Kirstine Nørregaard and Jensen, Lisette Okkels and Maeng, Michael and Christensen, Martin Kirk and Noori, Manijeh and Kahlert, Johnny and Jakobsen, Lars and Junker, Anders and Freeman, Phillip and Ellert-Gregersen, Julia and Raungaard, Bent and Terkelsen, Christian Juhl and Veien, Karsten Tange and Christiansen, Evald Høj},
title = {Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2023},
doi = {10.1161/circinterventions.122.012332}
}
EUVIMED